Suchergebnisse - "Davies, Jane C"

PubPharm (5)

1

The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6-11 with cystic fibrosis in a real-world setting

enthalten in: Respiratory research | 2023

von McNally, P. | Linnane, B. | Williamson, M. | +9

2

Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation : a phase 3, open-label, extension study

enthalten in: The Lancet. Respiratory medicine | 2021

von Chilvers, M. | Davies, J. | Milla, C. | +5

ErratumIn: Lancet Respir Med. 2021 Apr;9(4):e38. - PMID 33607008

3

Entering the era of highly effective modulator therapies

enthalten in: Pediatric pulmonology | 2021

von Dave, K. | Dobra, R. | Scott, S. | +4

4

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

enthalten in: The Lancet. Respiratory medicine | 2017

von Ratjen, F. | Hug, C. | Marigowda, G. | +62

CommentIn: Lancet Respir Med. 2017 Jul;5(7):536-537. - PMID 28606619

5

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

enthalten in: The New England journal of medicine | 2015

von Wainwright, C. | Elborn, J. | Ramsey, B. | +118

CommentIn: N Engl J Med. 2015 Jul 16;373(3):274-6. - PMID 25981385

1
[1]